MedTrace Logo

A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

NCT00752206 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2020-01-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine how long patients who undergo complete surgical removal of recurrent osteosarcoma in the lung will remain free of cancer after taking Saracatinib compared to patients taking placebo (a sugar pill).

Conditions

Interventions

DRUG

Saracatinib

Oral Agent

DRUG

Placebo

Oral Agent

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Sarcoma Alliance for Research through Collaboration

    lead OTHER

Principal Investigators

  • Kristin Baird, MD · National Cancer Institute - Pediatric Oncology Branch

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2017-08-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00752206 on ClinicalTrials.gov